Predictive value of the early response to chemotherapy in high‐risk stages II and III Hodgkin's disease

Cancer

Volumn 60, Issue 8, 1987, Pages 1713-1719

  Levis, Alessandro ^a   Vitolo, Umberto ^a   Vasino, Maria A Ciocca ^a   Cametti, Giovanni ^a   Urgesi, Alessandro ^b   Bertini, Marilena ^a   Canta, Marco ^a   Monetti, Ugo ^b   Bosio, Cesare ^c   Jayme, Augusto ^d   Resegotti, Luigi ^a  

^a Divisione di Ematologia   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Divisione di Radiodiagnostica ^*  (Italy)

^d MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; DIAGNOSIS; HODGKIN DISEASE; HUMAN; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; PROGNOSIS; SURVIVAL; THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MECHLORETHAMINE; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROGNOSIS; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; VINCRISTINE;

EID: 0023231052     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19871015)60:8<1713::AID-CNCR2820600804>3.0.CO;2-C     Document Type: Article

References (27)

1. Prognostic factors in pathological Stage III Hodgkin's disease
2. Anatomic substages of Stage IIIA Hodgkin's disease: Follow‐up of a collaborative study
3. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease
4. Hodgkin's disease with direct extension into pulmonary parenchyma from a mediastinal mass: A presentation requiring special therapeutic considerations
5. Second malignant neoplasm complicating Hodgkin's disease: The National Cancer Institute experience
6. Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group 10‐year follow‐up
7. Early response to chemotherapy as a prognostic factor in Hodgkin's disease
8. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy
9. Combination chemotherapy in the treatment of advanced Hodgkin's disease
10. Salvage chemotherapy with ABVD in MOPP‐resistant Hodgkin's disease
11. Non‐parametric estimation from incomplete information
12. Covariance analysis of censored survival data
13. Regression model and life tables (with discussion)
14. Combined modality therapy for advanced Hodgkin's disease: Long‐term follow‐up data
15. Stage III Hodgkin's disease: Improved survival with combined modality therapy as compared with radiation therapy alone
16. Chemotherapy and combined modality therapy for Hodgkin's disease: A progress report on Cancer and Leukemia Group B Studies
17. Hodgkin's disease and the non‐Hodgkin's lymphomas
18. Chemotherapy for diffuse large‐cell lymphoma: Rapidly responding patients have more durable remissions
19. Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ‐cell carcinoma
20. Drug resistance in cancer
21. Alternating drug combinations in the treatment of advanced Hodgkin's disease
22. Treatment of advanced Hodgkin's disease with chemotherapy and irradiation: Controlled trial of two versus three alternating, potentially non‐cross resistant combination
23. MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease
24. High‐dose chemotherapy and non‐frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy